Who is Gloria Allred? Well, let’s just say she’s no shrinking violet.
She’s also the lawyer of other alleged Tiger mistresses, including Rachel Uchitel.
Allred was not happy with Tiger’s public apology a few weeks ago. In fact, she blasted it as pathetic.
Allred has also been negotiating with Tiger’s attorneys for a settlement on behalf of her clients.
It seems reasonable to assume, therefore, that Allred could have orchestrated the release of today’s sext messages, with the message to Tiger’s attorneys being:
"How’d you like those, fellas? Lots more where those came from."
Was Allred behind this? Or did her client Joslyn James just take matters into her own hands? We contacted Allred and asked her to confirm whether the texts were from Tiger, whether James and Tiger are involved in any legal dispute and which of Tiger’s lady friends Allred is representing. She responded, via email, with a simple, "No comment."
Meanwhile, another question follows from this. Is this why Tiger hired George Bush’s press man, Ari Fleischer? Ari’s going to be busy today.
Either things in China are now very serious (and Jean-Claude Juncker has been hired as chief propaganda officer), or the BOC hired Erin Callan as CFO. Either way, for now at least, the Bank of China "is fine":
Then again, looking back in history, the instances when banks volunteered to being in default are... er... uhm.... not many.
The clampdown on China's shadow banking continues today, with Money Rates at Record Highs as PBOC Lets Cash Crunch Build China’s benchmark money-market rates climbed to records as the central bank refrained from using reverse-repurchase agreements to address a cash crunch in the world’s second-biggest economy.
The seven-day repurchase rate, which measures interbank funding availability, rose 270 basis points, or 2.70 percentage points, to 10.77 percent in Shanghai, according to a daily fixing announced by the National Interbank Funding Center. That was the highest in data going back to March 2003. The one-day rate rose by an unprecedented 527 basis points to an all-time high of 12.85 percent, a separate fixing sh...
The world has been watching every peep, sniffle, or innuendo associated with any voting member of the FOMC. What is the future of the latest in their ongoing market manipulation, in which money is printed to buy bonds to hold down interest rates, spur corporate borrowing, and artificially inflate stocks? Lately, that’s all investors have cared about.
Yes, it seems that all anyone has been talking about is the Federal Reserve and the timing of their “tapering” off on quant easing. There was a lot of anticipation going into this latest meeting. Fed chairman Bernanke said on Wednesday that if the economy continues to improve, their asset-purchasing program could start to wind down in late 2013 and conclude in 2014.
Stocks sold off on the news and Treasury yields spiked to 2011 highs. Int...
Curis, Inc. (Nasdaq: CRIS), an oncology-focused drug development company seeking to develop novel drug candidates for the treatment of various cancers, today announced the issuance of U.S. Patent No. 8,461,157, which claims methods of treating human diseases or disorders mediated by one or more of phosphoinositide 3-kinase (PI3K), mammalian target of rapamycin (mTOR) and histone deacetylase (HDAC) proteins, using compounds from a genus of small molecules with dual inhibitory properties, including but not limited to CUDC-907, a proprietary clinical stage dual inhibitor of PI3K and HDAC enzymes. This patent, along with another related patent issued in February 2013 (U.S. Patent No. 8,367,663), significantly enhances the intellectual property portfolio for Curis' proprietary chemical ent...
MU - Micron Technology, Inc. – Options traders appear to be snapping up out of the money call options on Micron Technology this morning ahead of the company’s third-quarter earnings report after the closing bell today. Shares in the name kicked off the trading session in rally mode, rising as much as 2.6% to a six-year high of $14.11 in the early going, but have since turned negative to stand 0.15% lower on the day at $13.73 as of 11:10 a.m. ET. Micron’s shares are up roughly 130% since this time last year. July expiry call optio...
With nothing of international significance to predetermine US market direction, the trade from the opening bell was one of marking time in advance of the June FOMC press release at 2 PM and more importantly Chairman Bernanke's hour-long press conference at 2:30. Prior to 2 PM the S&P 500 traded in a narrow negative range and hit its intraday high at 2:01 PM, up 0.04%, Then began a three-stage selloff. The first was a brief knee-jerk sell when the Fed summary was released, one that was essentially reversed a few minutes later. The second started about 15-minutes into Bernanke's press conference, again one that was partially reversed. The third selloff came during the final 30 minutes with no reversal. The index closed down 1.39%, a microscopic 0.02 points off its in...
No change to the statement as expected and Ben is speaking now. Basically he is dovish – one takeaway which I mentioned quite a few months ago but he reiterated today. The 6.5% unemployment rate is a threshold NOT a trigger. What that means is if inflation is benign when 6.5% unemployment returns, the Fed will be in no rush to raise interest rates. i.e. the goalposts are soft, nor hard. The market rallied on that… but it's not new news really.
Also the majority of members do not anticipate selling MBS off the balance sheet – this is part and parcel with the view that the balance sheet will not...
Reminder: OpTrader is available to chat with Members, comments are found below each post.
This post is for all our live virtual trade ideas and daily comments. Please click on "comments" below to follow our live discussion. All of our current trades are listed in the spreadsheet below, with entry price (1/2 in and All in), and exit prices (1/3 out, 2/3 out, and All out).
We also indicate our stop, which is most of the time the "5 day moving average". All trades, unless indicated, are front-month ATM options.
Please feel free to participate in the discussion and ask any questions you might have about this virtual portfolio, by clicking on the "comments" link right below.
To learn more about the swing trading virtual portfolio (strategy, performance, FAQ, etc.), please click here
Reminder: Craigzooka is available to chat with Members regarding his virtual portfolio performance, comments are found below each post.
I am going to share with you how I manage my IRA and the power of reducing your cost basis. My goal each year is a 20% return in my IRA. Sometimes I make it and sometimes I don't, but I believe that all of my success is due to reducing my cost basis. To illustrate the power of reducing your cost basis here are some trades we did last year. These trades are taken from an educational portfolio we ran in a paper-trading account for a little more than a year.
We bought RIG on 5/15/2012 for $44.13, sold it on 1/18/2013 for $46 but booked a profit of $1,154.
We bought MT on 1/4/2012 for $19.24, sold it on 12/21/2012 for $15 but booked a profit of $454.
We bought CHK on 1/27/2012 for $21.93, sold it on 10/19/2012 for $18 b...
Stock market posts another record setting week, but the big news came after Friday’s close.
Courtesy of NASA
The stock market put on another record setting show with the Dow Jones Industrial Average (NYSEARCA:DIA) closing at a record high 15,118 and the S&P 500 (NYSEARCA:SPY) closing at 1633.70, another all time closing high.
For the week, the Dow Jones Industrial Average (NYSEARCA:DIA) gained 1%, the S&P 500 (NYSEARCA:SPY) climbed 1.2%, the Nasdaq Composite (NYSEARCA:...
Reminder: Pharmboy is available to chat with Members, comments are found below each post.
Well, well, well....it is good to know that there are others in the scientific arena who believed that YMI Bioscience's data (cough - Gilead) is a better drug than Incyte's Jakafi. Now, the definitive data are still unknown, but there was enough evidence from a Phase 2 trial to take a small risk for a huge reward. So, let's forget about Apple (AAPL), and do nothing but biotechs from now until Congress passes universal health care coverage for prescriptions....and drive the prices down so that research and development is no longer feasible to conduct in the US. Even Seattle Genetics (SGEN) has been on a tear as of late...
Note: The material presented in this commentary is provided for informational purposes only and is based upon information that is considered to be reliable. However, neither Philstockworld, LLC (PSW) nor its affiliates warrant its completeness, accuracy or adequacy and it should not be relied upon as such. Neither PSW nor its affiliates are responsible for any errors or omissions or for results obtained from the use of this information. Past performance, including the tracking of virtual trades and portfolios for educational purposes, is not necessarily indicative of future results. Neither Phil, Optrader, or anyone related to PSW is a registered financial adviser and they may hold positions in the stocks mentioned, which may change at any time without notice. Do not buy or sell based on anything that is written here, the risk of loss in trading is great.
This material is not intended as an offer or solicitation for the purchase or sale of any security or other financial instrument. Securities or other financial instruments mentioned in this material are not suitable for all investors. Any opinions expressed herein are given in good faith, are subject to change without notice, and are only intended at the moment of their issue as conditions quickly change. The information contained herein does not constitute advice on the tax consequences of making any particular investment decision. This material does not take into account your particular investment objectives, financial situations or needs and is not intended as a recommendation to you of any particular securities, financial instruments or strategies. Before investing, you should consider whether it is suitable for your particular circumstances and, as necessary, seek professional advice.